FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Keeps Buy Opinion On Shares Of Alliancebernstein Holding L.p.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our 12-month target price by $3 to $43. We value AB shares at 10.8x our 2027 EPS estimate of $4.00 (lowered by $0.20) and 11.8x our 2026 EPS estimate of $3.65 (trimmed by $0.15). This compares with the one-year average forward multiple of 11.4x and a disparate peer average of 16x. AB shares represent partnership interests and currently yield 8.8%. We keep our 2026 revenue growth forecast of 3% to 7%. Q1 adjusted revenues rose 3.9% to $871M, in line with our forecast. AB noted its institutional pipeline totaled $27.5B at the end of Q1. The pipeline is set to benefit from strategic initiatives, including the planned expansion into Asia insurance markets. AUM grew 6.9% to $838.6B. However, net outflows deteriorated to $7.1B (from $2.4B of inflows a year ago), masking $6.7B of inflows into fixed income, alternatives, and multi-asset investments. Driven by restructuring actions, GAAP operating margins expanded 430 bps to 26.1%. We see additional operating margin expansion in 2026.

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Cincinnati Financial Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price by $7 to $185, valuing CINF shares (currently yielding 2%) at 20x our 2027 operating EPS estimate of $9.15 (raised by $0.10) and at 21.5x our 2026 EPS estimate of $8.60 (raised by $0.10), versus its five-year average forward multiple of 21x and peer average. CINF posted Q1 operating EPS of $2.10 versus a $0.24 operating loss per share a year ago, matching our estimate and topping the $1.94 consensus view, amid 12% higher operating revenues due to 11% premium growth and 14% higher net investment income, with written premium growth of 7% likely at the upper end of peer averages. We believe CINF's competitive strengths include its facile underwriting style and ability to allocate underwriting capital to areas with the most promising fundamentals, positioning it well despite increasingly competitive market conditions. CINF's ability to consistently produce above-peer growth and underwriting profitability will support the shares' premium valuation versus peers, in our view.

$CINF
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Linde Plc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $48 to $537, using a P/E of 27.1x, equal to LIN's average forward P/E over the last three years. We raise our 2026 EPS estimate by $0.05 to $18.03 and 2027 by $0.26 to $19.81. LIN reported Q1 adj. EPS of $4.33, beating consensus by $0.06, with 30% operating margins and 24% ROC demonstrating the resilience of its business model. Management raised the low end of full-year guidance to $17.60-$17.90 (7%-9% growth), citing confidence despite geopolitical headwinds. The $7.1B project backlog should reach $8B+ by year-end, driven by Electronics projects supporting AI chip manufacturing. Americas volumes grew 2% Y/Y with double-digit hardgoods growth, though EMEA remains challenged by weak industrial activity. Commercial space is emerging as a significant growth driver, with aerospace sales up double-digits. Helium supply tightness presents upside opportunity beyond guidance. We think shares are fully valued at 25.6x our 2027 EPS estimate, limiting upside potential in the near term.

$LIN
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Silgan Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $13 to $46, based on an EV/EBITDA of 8.9x our 2026 EBITDA estimate, in line with SLGN's three-year average multiple. We increase our 2026 EPS estimate by $0.05 to $3.90 and raise 2027's by $0.05 to $4.20. Metal containers started the year strong, up 2% Y/Y, with pet food product volume up 11%. Management continues to see a long runway for growth in the fragrance, beauty, and health care category now that it is fully integrated into the Weener portfolio. We anticipate further product launches and customer partnerships in 2027, driving growth in this space. Dispensing and specialty closures headwinds are due to higher-cost inventory with volumes adversely affected by severe weather events in North America. Management also noted that volume is likely to improve in 2H 2026 after securing new business wins that have yet to be commercialized but were secured earlier this year.

$SLGN